XLON
DEMG
Market cap873kUSD
Feb 20, Last price
0.02GBP
Name
Deltex Medical Group PLC
Chart & Performance
P/E
—
P/S
0.37
EPS
—
Div Yield, %
—
Shrs. gr., 5y
20.16%
Rev. gr., 5y
-18.55%
Revenues
2m
-28.44%
Net income
-1m
L+11.58%
CFO
-1m
L+97.19%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Deltex Medical Group plc, together with its subsidiaries, manufactures, markets, and sells oesophageal doppler haemodynamic monitoring systems under the TrueVue name in the United Kingdom, the United States, Spain, Canada, and internationally. It offers esophageal Doppler Probes that is used to measure a patient's central vascular blood flow and fluid status to measure real time blood velocities within the descending aorta; Loops plots aortic blood flow velocity and aortic blood pressure monitoring throughout every heartbeat; High Definition Impedance Cardiography, a non-invasive cardiac function and fluid status monitoring system for awake patients; and PressureWave, a pulse pressure waveform analysis algorithm used during periods of instability or for periods when the ODM mode is unavailable. The company also provides Deltex Medical Esophageal Doppler Simulator that enables clinicians to practice probe insertion, focusing, and waveform interpretation outside of a patient setting. Its products are used in Covid-19 critical care; sepsis; major abdominal, laparoscopic, and spinal surgeries; cardiac, trauma, and transplant procedures; and post-operative acute kidney injury monitoring. Deltex Medical Group plc was incorporated in 2000 and is headquartered in Chichester, the United Kingdom.
Valuation
Title GBP in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||